Intended for healthcare professionals


NICE endorses new drug to prevent myocardial infarctions and strokes

BMJ 2022; 377 doi: (Published 13 June 2022) Cite this as: BMJ 2022;377:o1444
  1. Jacqui Wise
  1. Kent

Patients with established cardiovascular disease and raised triglyceride concentrations, despite taking statins, can be prescribed icosapent ethyl to reduce the risk of cardiovascular events, the UK National Institute for Health and Care Excellence has recommended.1

Icosapent ethyl (marketed as Vazkepa) is the first licensed treatment shown to reduce the risk of cardiovascular events such as myocardial infarctions and strokes in people with controlled low density lipoprotein cholesterol (LDL-C) who are taking a statin and who have triglyceride …

View Full Text

Log in

Log in through your institution


* For online subscription